FLUORESCEIN
- Product NDC
- 83854-048
- Requested package NDC
- 83854-048-12
- 11-digit product format
- 838540048
- Labeler code
- 83854
- Product ID
- 83854-048_5c448a5e-458f-469c-9f1f-417c051b5c15
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- fluorescein
- Dosage form
- INJECTION
- Route
- INTRAVENOUS
- Labeler
- Anthea Pharma Private Limited
- Application
- ANDA218651
- Marketing category
- ANDA
- Marketing start
- 2026-10-14
- Substance
- FLUORESCEIN SODIUM
- Active strength
- 100 mg/mL
- Pharmacologic classes
- Diagnostic Dye [EPC], Dyes [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A218651-001 | FLUORESCEIN SODIUM | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | |
| A218651-002 | FLUORESCEIN SODIUM | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A218651-001 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A218651-001 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A218651-001 | AP | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A218651-001 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A218651-001 | AP | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218651-001 | AP | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- FLUORESCEIN
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| FLUORESCEIN SODIUM | 100 mg/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 93X55PE38X | Internal UNII lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| fbf07435-b6c0-49a5-a393-44617e3f451a | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| FLUORESCEIN | FLUORESCEIN | Anthea Pharma Private Limited | fbf07435-b6c0-49a5-a393-44617e3f451a | 2026-10-14 | 218651 ANDA218651 83854-048-12 83854-048 83854004812 | |
| Fluorescein | FLUORESCEIN | Zydus Pharmaceuticals USA Inc. | 19aea137-3f47-4b69-9884-3bff5f79b04a | 2026-09-14 | Warnings, Adverse reactions | 218651 ANDA218651 |
| Fluorescein | FLUORESCEIN | Zydus Lifesciences Limited | 5c88e2a2-b05c-46f2-9874-c935e4b96a6e | 2026-06-02 | 218651 ANDA218651 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 83854-048-12 | 83854004812 | 12 VIAL, SINGLE-DOSE in 1 CARTON (83854-048-12) / 5 mL in 1 VIAL, SINGLE-DOSE (83854-048-01) | 2026-10-14 | No | No | Current |